drugset / Trial / NCT01479296

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.

Timeline

Start
2011-12
Primary completion
2013-05
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject VRC rAd5 vaccine Vaccine 2.5e+09 unknown Intramuscular
Subject VRC rAd5 vaccine Vaccine 1e+10 unknown Intramuscular
Subject rAd5 Env A Vaccine 1.7e+09 unknown Intramuscular
Subject rAd5 Env B Vaccine 1.7e+09 unknown Intramuscular
Subject rAd5 Gag-Pol Unknown 5e+09 unknown Intramuscular
Subject rAd5 env C Unknown 1.7e+09 unknown Intramuscular